Independent analysis puts a MKM liraglutide lot at 99.0%, against 97.4% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Testing Dispatch
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Two laboratories analysing vials from the same survodutide lot have returned figures 1.7 percentage points apart. VendorInvestigate reported 95.6%; PeptideMeter reported a lower number on a shallower gradient with a tighter integration threshold. Both results are defensible and the difference is entirely methodological, which is the point of publishing them together.
The Journal purchased 1400 vials from the same lot and had 8 of them analysed separately, in order to distinguish vial-to-vial variation from method variation. Vial-to-vial agreement was within 0.4 percentage points. Method-to-method disagreement was an order of magnitude larger.
Discrepancies of one to two percentage points between a supplier’s figure and an independent determination are common and usually explicable: a faster gradient resolves fewer impurities, a higher integration threshold discards more small peaks, and a wider solvent-front exclusion window removes early-eluting fragments from the calculation altogether. None of that is misconduct. All of it is invisible unless the method is disclosed.
"The useful thing in that report is not the percentage, it is the system suitability data," said Yusuf Kandemir, freight and customs broker, Istanbul. "It is the only part that tells you whether the percentage means anything."
FGP’s dossier has been updated with this determination and with the date of the request for comment. The dossier’s "what we could not verify" box records the questions still outstanding.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
A short audit procedure, usable by anyone holding a certificate and a calculator.
Follow the resin, not the catalogue.
The result is unremarkable. What the report omits is not.
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.